Based on the provided data, the import of insulin to Sweden is forecasted to decline from 2024 to 2028, decreasing from a value of $200.33 thousand in 2024 to $151.75 thousand in 2028. Comparing the years 2024 and 2025, there is a year-on-year decrease of approximately 6.2%. From 2025 to 2026, the reduction is around 6.5%, while from 2026 to 2027, it is approximately 6.8%. The trend continues from 2027 to 2028, with a decline of about 7.2%. Over the analyzed period, the Compound Annual Growth Rate (CAGR) reflects an average annual decrease of approximately 6.7%.
Future trends to watch for include potential shifts in healthcare policies, advancements in diabetes treatment technologies and alternatives, changes in supplier dynamics, global insulin market fluctuations, and potential economic factors impacting Sweden's healthcare budget and importation capabilities.
